Hamlet Pharma

 The Board of Hamlet BioPharma has today decided to appoint Catharina Svanborg as CEO. Catharina immediately assumes the CEO role and continues as a Board member. Martin Erixon leaves the CEO role and will be at the company's disposal during his notice period. Board member Magnus Nylén was appointed by the board as temporary chairman of the board. The board decided to call an extraordinary general meeting to propose Professor Gabriela Godaly to be elected as a new board member and Chairman of the board. Notice will be sent shortly.

Gabriela Godaly is Professor of Clinical microbiology at Lund University and has extensive experience of research and drug development at Lund University and at Gambro Lundia AB.

Professor Godaly is familiar with Hamlet BioPharma and has been actively involved in its development for several years. She served on the Board of Directors of SelectImmune Pharma prior to its merger with Hamlet Pharma.

Professor Godaly is a clinical trials expert, especially in the area of critically ill patients, infectious disease and tuberculosis and her contributions are extremely valuable for the rapidly evolving clinical trials program of Hamlet BioPharma. 

This recruitment strengthens the drug development profile of Hamlet BioPharma.

For more information, please contact:

Magnus Nylén

Acting Chairman of the Board

Phone: +46 705759792

E-mail: catharina.svanborg@hamletbiopharma.com

magnus.nylen@partnerfk.se

Catharina Svanborg

CEO

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@hamletbiopharma.com